Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/119701
Title: | Interferon regulatory factor 5 genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis |
Author: | García-Bermúdez, Mercedes López Mejías, Raquel Genre, Fernanda Castañeda, Santos Llorca Díaz, Javier González Juanatey, Carlos Corrales, Alfonso Ubilla, Begoña Miranda-Filloy, José A. Pina, Trinitario Gómez Vaquero, Carmen Rodríguez-Rodríguez, Luis Fernández-Gutiérrez, Benjamín Balsa, Alejandro Pascual-Salcedo, Dora López Longo, Francisco J. Carreira, Patricia Blanco, Ricardo Martín, Javier González-Gay, Miguel A. |
Keywords: | Artritis reumatoide Malalties cardiovasculars Interferó Espanya Rheumatoid arthritis Cardiovascular diseases Interferon Spain |
Issue Date: | 10-Jul-2014 |
Publisher: | BioMed Central |
Abstract: | Introduction: Rheumatoid arthritis (RA) is a complex polygenic inflammatory disease associated with accelerated atherosclerosis and increased cardiovascular (CV) disease risk. Interferon regulatory factor 5 (IRF5) is a regulator of type I interferon induction. Recently, researchers have described an association between multiple single-nucleotide polymorphisms of the IRF5 gene and some rheumatic disorders. In this study, we aimed to evaluate whether three different haplotype blocks within the IRF5 locus which have been shown to alter the protein function are involved in the risk of CV events occurring in Spanish RA patients. Methods: Three IRF5 polymorphisms (rs2004640, rs2070197 and rs10954213) representative of each haplotype group were genotyped by performing TaqMan assays using a 7900HT Fast Real-Time PCR System with tissue from a total of 2,137 Spanish patients diagnosed with RA. Among them, 390 (18.2%) had experienced CV events. The relationship of IRF5 genotypes and haplotypes to CV events was tested using Cox regression. Results: Male sex, age at RA diagnosis and most traditional risk factors (hypertension, dyslipidemia and smoking habit) were associated with increased risk for CV events in the RA population. Interestingly, a protective effect of both IRF5 rs2004640 GG and IRF5 rs10954213 GG genotypes against the risk for CV events after adjusting the results for sex, age at RA diagnosis and traditional CV disease risk factors was observed (hazard ratio (HR) = 0.6, 95% confidence interval (CI) = 0.38 to 0.92, P = 0.02; and HR = 0.58, 95% CI = 0.36 to 0.95, P = 0.03, respectively). Moreover, we detected a protective effect of the GTG haplotype against the risk for CV events after adjusting the results for potential confounding factors (HR = 0.72, 95% CI = 0.56 to 0.93, P = 0.012). Conclusions: Our results reveal that IRF5 gene variants are associated with risk of CV events in patients with RA. |
Note: | Reproducció del document publicat a: https://doi.org/10.1186/ar4608 |
It is part of: | Arthritis Research & Therapy, 2014, vol. 16, num. 4, p. R146 |
URI: | http://hdl.handle.net/2445/119701 |
Related resource: | https://doi.org/10.1186/ar4608 |
ISSN: | 1478-6362 |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
649895.pdf | 278.95 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License